1. Home
  2. QSI vs SGMT Comparison

QSI vs SGMT Comparison

Compare QSI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum-Si Incorporated

QSI

Quantum-Si Incorporated

HOLD

Current Price

$0.81

Market Cap

165.6M

Sector

Health Care

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$10.86

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
QSI
SGMT
Founded
2013
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.6M
169.4M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
QSI
SGMT
Price
$0.81
$10.86
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$1.00
$26.13
AVG Volume (30 Days)
3.2M
1.3M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
28.17
N/A
EPS
N/A
N/A
Revenue
$2,436,000.00
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$618.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$4.50
52 Week High
$3.10
$11.15

Technical Indicators

Market Signals
Indicator
QSI
SGMT
Relative Strength Index (RSI) 52.92 65.37
Support Level $0.70 $6.55
Resistance Level $1.06 $11.15
Average True Range (ATR) 0.07 0.61
MACD 0.01 0.01
Stochastic Oscillator 53.26 61.85

Price Performance

Historical Comparison
QSI
SGMT

About QSI Quantum-Si Incorporated

Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: